

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS & FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
STARRED QUESTION NO. †*182
TO BE ANSWERED ON 29th July, 2022

Increase in Prices of Drugs

†*182. SHRI SADASHIV KISAN LOKHANDE:

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the percentage increase in prices of drugs during the last five years;
- (b) whether permission has been sought from the Government to increase the prices of any drugs;
- (c) if so, the details of permission granted to increase the prices of drugs including the names thereof; and
- (d) the details of the drugs whose prices have come down or have been reduced?

ANSWER

**MINISTER IN THE MINISTRY OF CHEMICALS & FERTILIZERS
(DR. MANSUKH MANDAVIYA)**

(a) to (d): A statement is laid on the Table of the House.

Statement referred to in reply to Lok Sabha Starred Question No. †*182 for answer on 29.07.2022 regarding Increase in Prices of Drugs.

(a): As per extant provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), the ceiling prices of scheduled formulations as per Schedule-I of DPCO, 2013 based on the National List of Essential Medicines (NLEM) issued by the Ministry of Health & Family Welfare (MoH&FW) are fixed by the National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals. All manufacturers of scheduled medicines are required to sell their products within the ceiling price (plus applicable Goods and Service Tax) fixed by the NPPA. Annual revision of ceiling prices of scheduled medicines is permissible based on Wholesale Price Index (WPI) for all commodities for the preceding calendar year. The Compounded Annual Growth Rate (CAGR) of WPI for the last 5 years is 4.12%. In respect of non-scheduled formulations, while a manufacturer can fix its Maximum Retail Price (MRP) but cannot increase the same by more than 10% of what was prevalent during the preceding 12 months. Further, WPI increase in case of scheduled drugs and 10% increase in case of non-scheduled drugs is the maximum increase permissible, which may or may not be availed. The manufacturers normally decide the market price of their drugs based on market dynamics, within the ceiling, wherever prescribed, by NPPA.

(b) & (c): NPPA had received applications for upward price revision of 74 formulations claiming increase in price of Active Pharmaceutical Ingredients (APIs), increase in cost of production, exchange rate variations, repeated price control, etc. which had resulted in unviability in sustainable production and marketing of various drugs. Considering these applications, NPPA allowed one-time price increase of up to 50% on the then applicable ceiling price in public interest as an exceptional measure by invoking para 19 of the DPCO, 2013 as under:

- Heparin Injection 5000 IU/ml and 1000IU/ml in June, 2020.
- 21 scheduled formulations of 12 medicines in December, 2019;
- 9 scheduled formulations of 3 drugs in July 2021.

The details of price revision as notified by NPPA vide S.O. No. 4461 (E) dated 13.12.2019 and S.O. 2654(E) dated 01.07.2021 respectively are attached as **Annexure**.

(d): NPPA has fixed ceiling prices of 890 scheduled formulations across various therapeutic categories including scheduled medical devices, viz., Intra Uterine Devices (IUD), condoms and coronary stents and retail price of approx. 2,023 new drugs. Further, it has capped the price of Liquid Medical Oxygen (LMO) and Oxygen Inhalation (Medicinal gas) in cylinders.

Further, the details of drugs, including medical devices, for which prices have been reduced under Para 19 of DPCO, 2013 in public interest are as under:

- a. Fixed ceiling price of Orthopaedic Knee Implants.
- b. Capped MRP of 106 non-scheduled drug formulations, including 22 diabetic and 84 cardiovascular drugs.
- c. Capped Trade Margin of non-scheduled formulations of 42 select Anti-cancer medicines as a pilot for proof of concept.
- d. Regulated price of Oxygen Concentrators, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer and Glucometer under 'Trade Margin Rationalisation' Approach during COVID period.

The details of ceiling prices and retail prices of various formulations fixed by NPPA are available at its website at nppaindia.nic.in.

Annexure

Details of Price revision of drugs notified by NPPA vide S. O. No. 4461 (E) dated 13.12.2019

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Existing S.O. No. & Date	
(1)	(2)	(3)	(4)	(5)	6(a)	6(b)
1	BCG vaccine		Each Dose	8.75	1485(E) Sl. No. 95	29.03.2019
2	Benzathine benzylpenicillin	Powder for Injection 12 lac units	Each Pack	17.84	1485(E) Sl. No. 96	29.03.2019
3	Benzathine benzylpenicillin	Powder for Injection 6 lac units	Each Pack	11.81	1485(E) Sl. No. 97	29.03.2019
4	Benzyl penicillin	Powder for Injection 10 Lac Units	Each Pack	7.64	1485(E) Sl. No. 100	29.03.2019
5	Chloroquine	Tablet 150mg	1 Tablet	1.16	1485(E) Sl. No. 176	29.03.2019
6	Dapsone	Tablet 100 mg	1 Tablet	0.35	1485(E) Sl. No. 243	29.03.2019
7	Furosemide	Tablet 40 mg	1 Tablet	0.74	1485(E) Sl. No. 344	29.03.2019
8	Furosemide	Injection 10mg/ml	1 ml	2.43	1485(E) Sl. No. 345	29.03.2019
9	Metronidazole	Oral Liquid 200 mg/5ml	1 ml	0.44	1485(E) Sl. No. 555	29.03.2019
10	Metronidazole	Tablet 200 mg	1 Tablet	0.68	1485(E) Sl. No. 556	29.03.2019
11	Metronidazole	Tablet 400 mg	1 Tablet	1.25	1485(E) Sl. No. 557	29.03.2019
12	Metronidazole	Injection 500mg/100ml	1 ml	0.20	1485(E) Sl. No. 554	29.03.2019
13	Ascorbic Acid (Vitamin C)	Tablet 500 mg	1 Tablet	1.34	1485(E) Sl. No. 74	29.03.2019
14	Co-trimoxazole (Sulphamethoxazole (A)+ Trimethoprim (B))	Tablet 400 mg(A)+80 mg(B)	1 Tablet	0.77	1485(E) Sl. No. 227	29.03.2019
15	Co-trimoxazole (Sulphamethoxazole (A)+ Trimethoprim (B))	Tablet 800 mg(A)+160 mg(B)	1 Tablet	1.98	1485(E) Sl. No. 228	29.03.2019
16	Co-trimoxazole (Sulphamethoxazole (A)+ Trimethoprim (B))	Oral Liquid 200mg(A)+40mg(B)/5ml	1 ml	0.32	1485(E) Sl. No. 226	29.03.2019

17	Pheniramine	Injection 22.75 mg/ml (10ml pack)	1 ml	1.67	1485(E) Sl. No. 639	29.03.2019
18	Pheniramine	Injection 22.75 mg/ml (2ml pack)	1 ml	2.24	1485(E) Sl. No. 638	29.03.2019
19	Prednisolone	Drops 1%	1 ml	4.92	1485(E) Sl. No. 672	29.03.2019
20	Clofazimine	Capsule 50 mg	1 Capsule	2.13	1485(E) Sl. No. 199	29.03.2019
21	Clofazimine	Capsule 100 mg	1 Capsule	3.63	1485(E) Sl. No. 198	29.03.2019

Details of Price revision of drugs notified by NPPA vide S.O. 2654(E) dated 01.07.2021

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Existing S.O. No. & Date	
(1)	(2)	(3)	(4)	(5)	6(a)	6(b)
1.	Carbamazepine	Oral Liquid 100 mg/5ml	1 ml	0.29	1330(E) Sl. No. 139	25.03.2021
2.	Carbamazepine	CR Tablet 200 mg	1 tablet	2.34	1330(E) Sl. No. 140	25.03.2021
3.	Carbamazepine	CR Tablet 400 mg	1 tablet	4.61	1330(E) Sl. No. 141	25.03.2021
4.	Carbamazepine	Tablet 100 mg	1 tablet	1.02	1330(E) Sl. No. 142	25.03.2021
5.	Ranitidine	Oral Liquid 75 mg/5ml	1 ml	1.08	1330(E) Sl. No. 722	25.03.2021
6.	Ranitidine	Tablet 150 mg	1 tablet	1.10	1330(E) Sl. No. 723	25.03.2021
7.	Ranitidine	Injection 25mg/ml	1 ml	2.43	1330(E) Sl. No. 724	25.03.2021
8.	Ibuprofen	Tablet 200 mg	1 tablet	0.59	1330(E) Sl. No. 431	25.03.2021
9.	Ibuprofen	Tablet 400 mg	1 tablet	1.04	1330(E) Sl. No. 432	25.03.2021
